The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis

Korean Circulation Journal

Volumn 41, Issue 11, 2011, Pages 641-648

  Lee, Kyounghoon ^a   Ahn, Tae Hoon ^a   Kang, Woong Choi ^a   Han, Seung Hwan ^a   Choi, In Suck ^a   Shin, Eak Kyun ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Coronary stenosis; HMG CoA reductase; Inflammation; Intravascular ultrasonography; Niacin

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MALE; OXIDATIVE STRESS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84255171045     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.11.641     Document Type: Article

References (29)

1. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9. (Pubitemid 26338729)
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
5. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four Prospective American Studies. Circulation 1989;79:8-15. (Pubitemid 19043669)
6. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:C69-77.
7. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
8. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004;15:659-65. (Pubitemid 39612984)
9. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug: a 50th anniversary review. J Intern Med 2005,258:94-114. (Pubitemid 41025967)
10. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001;21:1783-9. (Pubitemid 34219783)
11. Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag 2007;3:159-64. (Pubitemid 46860725)
12. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50. (Pubitemid 44789989)
13. Mintz GS, Nissen SE, Anderson WD, et al. A report of the American College of Cardiology Task Force on clinical expert consensus documents. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). J Am Coll Cardiol 2001;37:1478-92.
14. Park SY, Kwak JJ, Park SH. Dose dependent changes of lipid profiles, IL-6 and CRP in unstable angina patients after simvastatin therapy Korean Circ J 2003;33:663-70.
15. Son JW, Koh KK. Effects of statins on endothelium: vasomotor function, inflammation, and hemostasis. Korean Circ J 1999;29:1016-31.
16. Hong YJ, Jeong MH, Ahn YK, et al. Effect of conventional dose of simvastatin on plaque regression and vascular remodeling in the peristent reference segments of normocholesterolemic patients: a serial intravascular ultrasound assessment. Korean Circ J 2007;37:483-8.
17. Hong YJ, Jeong MH, Lim JH, et al. The prognostic significance of statin therapy according to the level of C-reactive protein in acute myocardial infarction patients who underwent percutaneous coronary intervention. Korean Circ J 2003;33:891-900.
18. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65.
19. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. (Pubitemid 33126837)
20. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7. (Pubitemid 39612564)
21. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002;106:399-402. (Pubitemid 34803680)
22. Tomai F, Crea F, Gaspardone A, et al. Unstable angina and elevated c-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 2001;104:1471-6. (Pubitemid 32917337)
23. Fichtischerer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease Circulation 2000;102:1000-6. (Pubitemid 30657516)
24. Son JW, Koh KK, Ahn JY, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82. (Pubitemid 36351413)
25. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 1999;82:1730-5.
26. Lelongt B, Bengatta S, Delauche M, Lund LR, Werb Z, Ronco PM. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med 2001;193:793-802. (Pubitemid 32524529)
27. Fontaine V, Jacob MP, Houard X, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002;161:1701-10. (Pubitemid 35265529)
28. Tang J, Liu J, Zhou C, et al. Mmp-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice. J Cereb Blood Flow Metab 2004;24:1133-45. (Pubitemid 39332152)
29. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 2005;102:15575-80. (Pubitemid 41528098)